绥美凯价格

On January 20, 2018, ViiV, a joint venture company under GlaxoSmithKline (hereinafter referred to as GSK), the first complete antiviral treatment regimen drug with dolutegravir (also known as DTG in English) as the core, was officially launched in China. This is also the first complete single-pill compound treatment regimen in the field of HIV treatment in China.

Suimeikai is composed of three ingredients: DTG (DTG) + Abacavir (ABC) + Lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. In 2016, GSK launched the integrase DTG (Trivic) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time, Trimic uses DTG, an integrase inhibitor, as the core drug, combined with a treatment plan of two backbone drugs, abacavir and lamivudine, and made a single-tablet treatment for promotion, making great progress in the core drug in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

Trimax is the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection. Regarding the price of Suimeikai, the original drug is relatively expensive in China. Produced by the Indian company Emcure (Inbec), a box of 30 tablets sells for about RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices.